Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD

IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY

Journal of Clinical and Experimental Hepatology Pub Date : 2025-05-16 DOI:10.1016/j.jceh.2025.102590

Ajay Duseja , Arka De , Shivaram P. Singh , Kaushal Madan , Padaki N. Rao , Akash Shukla , Gourdas Choudhuri , Sanjiv Saigal , Shalimar , Anil Arora , Anil C. Anand , Ashim Das , Ashish Kumar , Chundamannil E. Eapen , Krishnadas Devadas , Kotacherry T. Shenoy , Manas Panigrahi , Manav Wadhawan , Manish Rathi , Narendra S. Choudhary , Yogesh K. Chawla

{"title":"Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD","authors":"Ajay Duseja , Arka De , Shivaram P. Singh , Kaushal Madan , Padaki N. Rao , Akash Shukla , Gourdas Choudhuri , Sanjiv Saigal , Shalimar , Anil Arora , Anil C. Anand , Ashim Das , Ashish Kumar , Chundamannil E. Eapen , Krishnadas Devadas , Kotacherry T. Shenoy , Manas Panigrahi , Manav Wadhawan , Manish Rathi , Narendra S. Choudhary , Yogesh K. Chawla","doi":"10.1016/j.jceh.2025.102590","DOIUrl":null,"url":null,"abstract":"<div><div>The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of ‘fatty and alcohol’ and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 5","pages":"Article 102590"},"PeriodicalIF":3.3000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0973688325000908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of ‘fatty and alcohol’ and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.

查看原文本刊更多论文

印度国家肝脏研究协会（INASL）采用代谢功能障碍相关脂肪变性肝病（MASLD）的新命名法：对INASL NAFLD指南文件的影响

从非酒精性脂肪性肝病（NAFLD）到代谢功能障碍相关脂肪性肝病（MASLD）的转变反映了肝病学的范式转变，强调代谢功能障碍是MASLD患者的主要驱动因素。这一包容性术语得到了包括印度全国肝脏研究协会（INASL）在内的70多个国际组织的认可，减少了“脂肪和酒精”的污名，并允许其他肝脏疾病病因与MASLD共存。在本评论中，我们讨论了在德尔菲共识达成之前的2023年发表的INASL NAFLD指导文件中采用新的MASLD命名法的含义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊